Skip to main content

What the FDA labels say about taking them together

Eplerenone and potassium citrate

Potassium citrate's FDA label of December 2, 2021 names eplerenone in its drug interactions section; the eplerenone label PlainMeds reads does not name potassium citrate.

Check it at the source: the eplerenone FDA label on DailyMed (effective June 23, 2025, Viatris Specialty LLC); the potassium citrate FDA label on DailyMed (effective December 2, 2021, Mission Pharmacal Company).

What does the eplerenone label say about potassium citrate?

Eplerenone's label (effective June 23, 2025) does not name potassium citrate in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Inspra), NDA021437 (Upjohn), as published by Viatris Specialty LLC, effective June 23, 2025 (SPL set 1a52bedc-8e2c-4116-a296-a87770676b4a), via openFDA; the full label on DailyMed

What does the potassium citrate label say about eplerenone?

Potassium citrate label, drug interactions

Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.

Source: FDA drug label (UROCIT-K), Mission Pharmacal Company, effective December 2, 2021 (SPL set 72cdea1b-2240-41db-987d-86d5c6aaa978), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Eplerenone generic labelers
12Potassium citrate generic labelers
EplerenonePotassium citrate
Labeled forHeart failure, High blood pressuren/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.308 per tablet 25 mg tablet$0.175 per tablet 10 mEq tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?